Skip to content 
The number of ipos in Hong Kong has increased by one again!
Enterprises in the Nanjing area are making every effort to enter the capital market
The “listing boom” has arrived ~
Recently, the Nanjing Area of China (Jiangsu) Pilot Free Trade Zone has once again brought good news – TRIAPEX LABORATORIES CO., LTD.(Triapex Laboratories), a company in the area, has submitted its prospectus to the Hong Kong Stock Exchange, planning to list on the main board of the Hong Kong Stock Exchange.
Dingtai Pharmaceutical Research
Dingtai Pharmaceutical Research was established in 2008 as a new type of contract research organization (CRO) company dedicated to providing integrated solutions based on disease biology for global pharmaceutical companies and research institutions. Through this business model, the company has transcended the traditional role of a CRO as an external service provider undertaking scattered tasks and transformed into a strategic R&D partner for its clients.
Dingtai Pharmaceutical Research offers comprehensive non-clinical safety, efficacy, and drug metabolism and pharmacokinetic (DMPK) studies, as well as integrated clinical trial services covering from proof-of-concept to key trials, thereby providing customers with full life-cycle R&D support. The company is highly focused on clinical value and has accumulated profound professional knowledge and rich experience in disease fields such as cardiovascular and metabolic diseases, central nervous system (CNS) diseases, ophthalmology, autoimmune diseases and tumors. According to Frost & Sullivan, in 2024, Dingtai Pharmaceutical Research was the largest CRO in the field of non-clinical research on cardiovascular and metabolic diseases in China in terms of related revenue.
According to Frost & Sullivan, Dingtai Pharmaceutical Research has established one of the most comprehensive combinations of non-human primate (NHP) disease models in China, supporting key non-clinical research in various disease areas. Thanks to its disease model project, Dingtai Pharmaceutical Research ranked as the third-largest CRO in China’s effectiveness research field in terms of related revenue in 2024.
As the core carrier of the biopharmaceutical industry in the Nanjing area of China (Jiangsu) Pilot Free Trade Zone, Yagu has currently gathered nearly 1,300 enterprises along the industrial chain. Through years of meticulous cultivation, it has successfully independently cultivated 7 listed companies, forming a clear hierarchy of potential listed reserve enterprises with considerable potential. The industrial ecosystem in the area has been continuously optimized, with a significant increase in innovation concentration and capital attraction capacity, injecting strong impetus into the rapid development of enterprises.
Since the beginning of this year, the listing process of enterprises in the Nanjing area has shown an “accelerated run” trend: Yaojie Ankang and Weilyilibo were the first to list on the Hong Kong Stock Exchange, firing a “double shot” of listing for the year. On August 25th, Yingshi Biotech officially submitted its application for listing on the Hong Kong Stock Exchange. On September 26th, the IPO application of Yingpai Pharmaceutical was accepted by the Hong Kong Stock Exchange. This time, Dingtai Pharmaceutical Research took over the listing application, further continuing the listing boom of enterprises in the region. This dynamic situation of seamless connection and layer-by-layer advancement not only reflects the strong innovative explosive power of the enterprises in the area, but also highlights the high recognition of the capital market for the industrial ecosystem and development model of the Medicine Valley.
In the future, the Nanjing area will accelerate the construction of a four-in-one, full-chain integrated biopharmaceutical industry innovation ecosystem featuring “learning, research, production and application”, helping more “new forces going public” move from the reserve pool to the capital market, and contributing more “pharmaceutical valley power” to China’s pharmaceutical innovation.
